Takeda Pharmaceutical Co. (TAK)
(Real Time Quote from BATS)
$13.10 USD
-0.13 (-0.98%)
Updated Apr 25, 2024 03:12 PM ET
1-Strong Buy of 5 1
A Value F Growth B Momentum C VGM
Income Statements
Fiscal Year end for Takeda Pharmaceutical Co falls in the month of March .
All items in Millions except EPS data.
3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 | |
---|---|---|---|---|---|
Sales | NA | 29,803 | 31,764 | 30,059 | 30,279 |
Cost Of Goods | NA | 9,206 | 9,851 | -9,347 | 10,026 |
Gross Profit | NA | 20,597 | 21,913 | 39,406 | 20,253 |
Selling & Adminstrative & Depr. & Amort Expenses | 0 | 16,967 | 17,812 | 15,926 | 19,329 |
Income After Depreciation & Amortization | 0 | 3,630 | 4,102 | 23,480 | 924 |
Non-Operating Income | NA | 402 | 74 | 993 | 35 |
Interest Expense | NA | 1,256 | 1,483 | 2,337 | 1,518 |
Pretax Income | NA | 2,776 | 2,693 | 3,443 | -559 |
Income Taxes | NA | 430 | 644 | -93 | -966 |
Minority Interest | NA | 0 | 1 | 2 | 0 |
Investment Gains/Losses | NA | 0 | 0 | 0 | 0 |
Other Income/Charges | NA | 0 | 0 | 0 | 0 |
Income From Cont. Operations | NA | 2,346 | 2,048 | 3,536 | 407 |
Extras & Discontinued Operations | NA | 0 | 0 | 0 | 0 |
Net Income (GAAP) | NA | 2,346 | 2,048 | 3,534 | 407 |
Depreciation Footnote | 3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 0 | 8,546 | 9,292 | 28,741 | 6,293 |
Depreciation & Amortization (Cash Flow) | NA | 4,917 | 5,190 | 5,261 | 5,370 |
Income After Depreciation & Amortization | 0 | 3,630 | 4,102 | 23,480 | 924 |
Earnings Per Share Data | 3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 |
---|---|---|---|---|---|
Average Shares | NA | 3,103.60 | 3,154.30 | 3,147.01 | 3,114.41 |
Diluted EPS Before Non-Recurring Items | NA | 2.07 | 1.89 | 1.98 | 1.78 |
Diluted Net EPS (GAAP) | NA | 0.75 | 0.65 | 1.12 | 0.13 |
Fiscal Year end for Takeda Pharmaceutical Co falls in the month of March .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 7,556.07 | 7,197.31 | 7,727.91 | 7,313.24 |
Cost Of Goods | NA | 2,580.47 | 2,370.72 | 2,344.13 | 2,366.33 |
Gross Profit | NA | 4,975.59 | 4,826.60 | 5,383.78 | 4,946.91 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 4,262.18 | 5,167.06 | 4,153.21 | 4,271.71 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 713.41 | -340.46 | 1,230.57 | 675.20 |
Non-Operating Income | NA | 160.99 | 78.55 | 190.07 | -447.15 |
Interest Expense | NA | 457.84 | 400.35 | 434.90 | -124.95 |
Pretax Income | NA | 416.57 | -662.26 | 985.74 | 352.98 |
Income Taxes | NA | -302.57 | -331.26 | 333.08 | 105.99 |
Minority Interest | NA | 0.24 | 0.41 | 0.08 | 0.02 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 719.14 | -331.00 | 652.66 | 246.99 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | 718.90 | -331.41 | 652.58 | 246.97 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 3,161.48 | 3,112.00 | 3,130.08 | 3,118.08 |
Diluted EPS Before Non-Recurring Items | NA | 0.51 | 0.50 | 0.55 | 0.39 |
Diluted Net EPS (GAAP) | NA | 0.23 | -0.11 | 0.21 | 0.08 |